drugset / Trial / NCT02288507
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety and efficacy of administering sorafenib concurrent with yttrium-90 radioembolization to patients with advanced hepatocellular cancer.
Timeline
- Start
- 2014-11
- Primary completion
- 2016-08
- Completion
- 2016-08
Outcome
Outcome not reported
Stopped (Enrollment): “Closed due to no accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 200 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |